Approaching MRD in Multiple Myeloma

(23:32)

MRD-Positive ALL: Personal Approaches to Treatment

(6:4)

Approaches to and the use of MRD in ALL

(5:17)

The challenge of persistent MRD in T-ALL \u0026 novel approaches being explored

(1:10)

Understanding MRD

(7:39)

The role of molecular MRD monitoring in AML/NGS approaches

(6:)

Applications of ctDNA in lung cancer: informing treatment approaches, MRD and screening

(2:2)

Next steps in myeloma research: MRD-driven studies, immunotherapy \u0026 approaching a cure

(1:23)

Dr. Litzow on MRD Assessment in ALL

(1:)

The potential use of multi-gene molecular MRD testing in AML

(1:)

MRD Testing in ALL: Sensitivity and Availability

(6:20)

MRD to determine risk of relapse after induction in AML

(2:25)

Combining New Therapies and MRD Approaches Across Lymphomas

(3:2)

The role of MRD in ALL: what defines a complete response?

(3:35)

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

(54:49)

MRD \u0026 Me

(8:18)

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

(2:10)

Should MRD-adaptive approaches be used in myeloma treatment?

(3:34)

Update on MRD, new approaches and clinical value in myeloma

(20:55)

How can MRD guide treatment of AML?

(1:39)